Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Cidara Therapeutics (CDTX) EBIT: 2017-2025

Historic EBIT for Cidara Therapeutics (CDTX) over the last 9 years, with Sep 2025 value amounting to -$88.6 million.

  • Cidara Therapeutics' EBIT fell 409.53% to -$88.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$195.5 million, marking a year-over-year decrease of 49.64%. This contributed to the annual value of -$176.1 million for FY2024, which is 550.78% down from last year.
  • According to the latest figures from Q3 2025, Cidara Therapeutics' EBIT is -$88.6 million, which was down 223.65% from -$27.4 million recorded in Q2 2025.
  • Cidara Therapeutics' 5-year EBIT high stood at $14.2 million for Q3 2022, and its period low was -$96.0 million during Q2 2024.
  • Over the past 3 years, Cidara Therapeutics' median EBIT value was -$17.4 million (recorded in 2024), while the average stood at -$30.4 million.
  • Its EBIT has fluctuated over the past 5 years, first surged by 178.68% in 2022, then plummeted by 1,322.41% in 2024.
  • Cidara Therapeutics' EBIT (Quarterly) stood at -$16.8 million in 2021, then grew by 19.58% to -$13.5 million in 2022, then surged by 35.49% to -$8.7 million in 2023, then crashed by 522.71% to -$54.2 million in 2024, then plummeted by 409.53% to -$88.6 million in 2025.
  • Its EBIT was -$88.6 million in Q3 2025, compared to -$27.4 million in Q2 2025 and -$25.3 million in Q1 2025.